29 Jul 2026 4 min read Western Hemisphere

Fertility Startup The American Baby Company Raises $4M to Open First Clinic

The American Baby Company CEO Van Spina and his fiancée

The American Baby Company, a fertility startup co-founded by CEO Van Spina and Chief Medical Officer Dr. Paul Magarelli, has raised US$4 million in a seed round led by Wormhole Capital and Tower Research Ventures to open its first clinic in West Palm Beach, Florida, this fall. Spina is a former technology investor at Warburg Pincus who previously founded a data business serving private credit markets; Magarelli is a double board-certified reproductive endocrinologist who developed a certification program training OB/GYNs to deliver fertility care and serves as dean of the clinical school at IVF Academy USA.

The company will offer a full IVF cycle for US$8,995 and egg freezing for US$4,995, both including medications, against a US national average that industry estimates place near US$23,500 per cycle. It aims to reach those prices through standardized, evidence-based protocols, AI-assisted patient intake, modernized lab workflows, and a staffing model that uses certification-trained generalist clinicians working under the oversight of fertility specialists. The clinic will initially focus on women under 35 with regular menstrual cycles and healthy ovarian reserve, referring more complex cases to outside specialists at no charge. The company says it wants to serve 250,000 patients a year within a decade and expand into additional US markets after West Palm Beach.

Market Context

The pricing gap the company is targeting is well documented: roughly one in eight American couples experiences infertility, but only about 14% of those affected pursue IVF, with cost consistently cited as the primary barrier. Roughly 400,000 IVF cycles are performed annually in the United States, a figure the company and its clinical partners argue is a fraction of underlying demand. Spina's thesis rests on price elasticity, arguing that each 1% reduction in cost drives roughly a 3% increase in utilization, and that the industry's default growth strategy has been to add billable procedures rather than reduce them.

The staffing model reflects a real supply constraint. The certification program Magarelli developed trains experienced OB/GYNs and advanced practice providers to deliver fertility care alongside reproductive endocrinologists, addressing a specialist shortage that its backers describe in stark terms. Research presented at the American Society for Reproductive Medicine's 2025 meeting reported that integrating these certified clinicians produced an 18% increase in new patients and a 9% increase in procedures, with outcomes described as non-inferior to those of board-certified reproductive endocrinologists. Federal policy has also shifted in the sector's direction: a February 2025 executive order directed agencies to expand IVF access and lower out-of-pocket costs, an October 2025 agreement with drugmaker EMD Serono cut list prices on common fertility drugs by as much as 84%, and the TrumpRx.gov platform launched in February 2026 to channel those discounts to patients.

The Signal

"IVF does not cost $30,000 as a matter of physics." — Van Spina, co-founder and CEO, The American Baby Company

Regional Relevance

For the United States: Fertility care has become an unusual point of bipartisan policy attention, tied to both healthcare affordability and rising concern over declining US birth rates, and a clinic offering IVF at roughly 40% of the national average price is a direct market test of whether cost, rather than demand, is what limits treatment volumes. If the model holds up clinically at scale, it would pressure a fee-for-service fertility industry where add-on procedures such as ICSI and preimplantation genetic testing are used in a majority of cycles despite contested evidence on their value for many patients. Federal efforts to cut drug costs give startups like this one a tailwind, since medications represent a substantial share of a cycle's total price.

For Florida: The choice of West Palm Beach places the company in a state with no general insurance mandate for infertility treatment, meaning Florida patients pay out of pocket in most cases, unlike those in the roughly 20 states with coverage requirements. That makes Florida both a harder market for patients and a cleaner proving ground for a cash-pay, transparent-pricing model, since there is no insurance reimbursement structure to work around. It also adds to South Florida's expanding healthcare and technology startup base, in a region whose rapid population growth has drawn both new residents of childbearing age and the capital that follows them.

The Other Side

Does the low price depend on treating only the easiest patients? By limiting its initial clinic to women under 35 with regular cycles and strong ovarian reserve, the company is selecting the population with the highest success rates and the most predictable protocols; that makes the economics far more manageable, but it also means the headline price may not extend to older patients or complex diagnoses, who represent a large share of people seeking IVF and whom the company says it will refer elsewhere.

Is the evidence behind the generalist staffing model strong enough? The claim that certification-trained OB/GYNs deliver outcomes non-inferior to reproductive endocrinologists comes from research presented at a conference by parties affiliated with the certification program itself; reproductive endocrinology is a subspecialty requiring years of additional fellowship training, and independent, peer-reviewed evidence at scale would carry more weight with regulators, referring physicians, and patients than a single conference presentation.

Can $4 million build a physical clinic network serving 250,000 patients a year? Fertility clinics are capital-intensive, requiring embryology labs, equipment, and licensed staff in every location, and a seed round of this size funds roughly one clinic; reaching the stated ten-year target would require repeated fundraising, disciplined replication of the model across markets, and success rates strong enough to sustain referrals, all in a sector where established chains and private equity-backed networks already compete for the same patients.